HanAll Biopharma Reports Third Quarter 2021 Results
HanAll\'s Partner HBM Completes First Dosing of Phase 2 of Batoclimab in TED in China
2021.10.20
HanAll Biopharma(KRX:
009420.KS) announced that its partner Harbour BioMed had completed the first
dosing of the first patient in Phase 2 of batoclimab in thyroid eye disease(TED)
in China.
For more
information, please refer to the link below.
- HBM\'s press
release link: https://www.harbourbiomed.com/news/168.html